Osocimab
Modify Date: 2025-10-01 14:35:49
Osocimab structure
|
Common Name | Osocimab | ||
|---|---|---|---|---|
| CAS Number | 2056878-75-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OsocimabOsocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1]. |
| Name | Osocimab |
|---|
| Description | Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Osocimab (1.4 nM-1 μM；30 分钟) 抑制凝血酶生成，同时抑制人血浆中 FXIa 介导的 FIX 激活 (或 FIX 转化) (IC50=16 nM) 和 FXIa 介导的底物裂解 (IC< sub>50=1.2 nM)[1]。 Osocimab (22.05 mg/mL) 抑制内在通路介导的凝血级联激活[1]。 |
| References |
| No Any Chemical & Physical Properties |